ClinicalTrials.gg
Drug

Apatinib clinical trials

Also written YN968D1 and Rivoceranib.

studies test it
428
open now
111
in phase 3
55
first study started
2007

How each study uses apatinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the apatinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Apatinib
227
Apatinib Mesylate
51
Apatinib Mesylate Tablets
34
Aitan
10
ATAN
5

Development codes

YN968D1
30

Other names

Rivoceranib
9
Rivoceranib Mesylate
2

In one entry with another drug

Given together, or one or the other

Camrelizumab plus Apatinib
7
Adebrelimab + Apatinib
5
Camrelizumab and Apatinib
4
Fluzoparib+Apatinib
3
Apatinib plus Camrelizumab
2
Fluzoparib Combined With Apatinib
2
TACE Plus Camrelizumab and Apatinib
2
Carilizumab and Apatinib
2

Studies by the year they started

427 studies that test it; most in 2017 (64); 1 more planned to start later

Studies that test apatinib, by start year
YearStudies
20071
20091
20103
20114
20121
20141
201512
201648
201764
201850
201946
202052
202136
202220
202317
202435
202523
202613

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
53
Phase 2
332
Phase 3
55
Phase 4
8
No phase
20

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 46 · Other 382

Jiangsu HengRui Medicine Co., Ltd. (33) · Sun Yat-sen University (24) · Fudan University (20) · Henan Cancer Hospital (16) · Tianjin Medical University Cancer Institute and Hospital (14) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (13) · Fujian Cancer Hospital (13) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (9)

Often tested with

Tested in the same studies.

Camrelizumab (111) · Adebrelimab (29) · Fluzoparib (19) · Paclitaxel (17) · Etoposide (9) · SHR-1701 (8) · Sintilimab (7) · Albumin-Bound Paclitaxel (7)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 4 phase 3 studies under way

Apatinib is the comparator. A study of two new drugs counts under both.

  • 1Tecotabart vedotin · LaNova Medicines Zhejiang Co., Ltd. · next primary completion Nov 2026
  • 1Thalidomide · Shanghai Zhongshan Hospital · next primary completion Jun 2030
  • 1Capecitabine · Shanghai Zhongshan Hospital · next primary completion Jun 2030
  • 1Disitamab vedotin · RemeGen Co., Ltd.
Reaching primary completion within a year · 26, 4 in phase 3

Studies that test apatinib, phase 3 first.

Studies

Open first, then newest update. How each study uses apatinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 428

See all 428 studies that test apatinib →

Given beside what is tested · 47 — apatinib is usual care or a partner of the new treatment

Showing 20 of 47.

As the comparator · 5 — what is tested is compared with apatinib

Codes

What other systems call apatinib · ClinicalTrials.gg INT005736

  • MeSH (NLM) C553458apatinibConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 5S371K6132RIVOCERANIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q27262801apatinibConfirmed FDA, NLM, Wikidata
  • DrugBank DB14765One source Wikidata

Also registered as rivoceranib mesylate (UNII TK02X14ASJ).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.